ライフサイエンスコーパス: placebo effect

1 trated to be effective only by virtue of the placebo effect.

2 been whether a given therapy has more than a placebo effect.

3 ble reports were demonstrating an element of placebo effect.

4 ge, denervation of ischemic myocardium and a placebo effect.

5 large proportion of patients experiencing a placebo effect.

6 antidepressant who improved as a result of a placebo effect.

7 hat light treatment has a benefit beyond its placebo effect.

8 emodynamic benefit, suggesting the role of a placebo effect.

9 t of therapeutic expectations, the so-called placebo effect.

10 drugs, possibly because of the integrated IA placebo effect.

11 We cannot reject the null hypothesis of no placebo effect.

12 was associated with a clinically significant placebo effect.

13 s even been ascribed to a "barbaric" form of placebo effect.

14 oups, but not at 6 months, denoting an early placebo effect.

15 TX) in descending modulation of pain and the placebo effect.

16 extended into clinically relevant models of placebo effect.

17 s opiate and dopamine, are involved with the placebo effect.

18 Some patients may respond, if only via a placebo effect.

19 d such study designs are very susceptible to placebo effect.

20 tion-the self in context-that is crucial for placebo effects.

21 h regular physical exercise, and nonspecific placebo effects.

22 , which can be difficult to distinguish from placebo effects.

23 anticipated to be susceptible to substantial placebo effects.

24 design mechanism to reduce the influence of placebo effects.

25 luid intelligence: specifically, the role of placebo effects.

26 merge as central brain structures underlying placebo effects.

27 logical systems involved in the formation of placebo effects.

28 epsy, and to identify methods of diminishing placebo effects.

29 mechanisms in theory and research regarding placebo effects.

30 and opioid transmitters on the formation of placebo effects.

31 urotransmission in regions known involved in placebo effects.

32 n the neurobiological mechanisms involved in placebo effects.

33 otentially having a role in the formation of placebo effects.

34 conditioning, provide signals that activate placebo effects.

35 d speech processing, thereby controlling for placebo effects.

36 ption-anticipation differentials, and actual placebo effects.

37 eptible to both placebo and nocebo (negative placebo) effects.

38 ement was most consistent with a substantial placebo effect; (3) longer, uncontrolled pacing periods

39 Three components bring forth the placebo effect: (a) positive beliefs and expectations on

40 Further examination of the placebo effect across the anxiety disorders may elucidat

41 one by reviewing current knowledge about the placebo effect and how it may pertain to alternative med

42 ns in the measurement of pain, the mind-body placebo effect and the impact of differences in the cond

43 enuine neuromodulation, (b) via non-specific placebo effects and (c) by demonstrating, through its im

44 ian interactions significantly contribute to placebo effects and clinical outcomes.

45 emonstrates that arginine vasopressin boosts placebo effects and that the effect of vasopressin depen

46 ions of clinical trials, the neurobiology of placebo effects and the implications of placebo effect f

47 al trials are now needed to exclude possible placebo effects and to determine whether fMRI-based neur

48 Placebo effects are beneficial health outcomes not relat

49 Placebo effects are especially prominent in Parkinson's

50 Therapeutic patterns that heighten placebo effects are especially prominent in unconvention

51 and in other fields of medicine suggest that placebo effects are likely to be an important aspect of

52 The observed placebo effect-associated pattern involved metabolic act

53 a specific antidepressant effect beyond its placebo effect, but it took at least 3 weeks for a signi

54 are important psychological determinants of placebo effects, but their underlying brain mechanisms a

55 Here, we explore the possibility to boost placebo effects by targeting pharmacologically the vasop

56 Placebo effects can be clinically meaningful and can riv

57 Differential placebo effects can substantially alter estimates of the

58 t nocebo effects, sometimes termed "negative placebo effects," can contribute appreciably to a variet

59 anism of action, and the contribution of the placebo effect cannot be quantified, this unmasked study

60 treatment for these patients, but presently placebo effects cannot be ruled out.

61 Besides the perspective that placebo effects confound randomized clinical trials, the

62 o clarify the psychological model underlying placebo effects could merge with the evolving neurobiolo

63 cts, perception-anticipation mismatches, and placebo effect development.

64 hanisms other than those associated with the placebo effect (e.g., conditioning, psychosocial context

65 a result of true drug effect (as opposed to placebo effect) exceed chance with pattern analysis.

66 ts when recommending a treatment with only a placebo effect for infants and toddlers with nonspecific

67 y of placebo effects and the implications of placebo effect for several disorders of neurological rel

68 the neurobiology of pain perception and the placebo effect has also played a role.

69 r understanding and conceptualization of the placebo effect has shifted in emphasis from a focus on t

70 Research and theory on placebo effects has illuminated much regarding the neuro

71 biological model to fulfill the promise that placebo effects have for improving patient outcomes.

72 They are also thought to underlie placebo effects, impacting perceptions and biological pr

73 ferent than active treatment in men, but the placebo effect in women was negligible and the treatment

74 ed trial whether patient expectancy mediates placebo effects in antidepressant studies.

75 Causes of placebo effects in antidepressant trials have been infer

76 ient expectancy is a significant mediator of placebo effects in antidepressant trials.

77 ions were employed to clarify the sources of placebo effects in epilepsy, and to identify methods of

78 uitment in an effort to evaluate the role of placebo effects in fluid intelligence gains from cogniti

79 This study examined placebo effects in pain by using positron-emission tomog

80 ique drama of this realm may have "enhanced" placebo effects in particular conditions.

81 k analysis to study the circuitry underlying placebo effects in PD subjects randomized to sham surger

82 ed to quantify and disentangle treatment and placebo effects in randomized clinical trials comparing

83 in many of these regions was correlated with placebo effects in reported pain.

84 tment, allowing a comparison of practice and placebo effects in the same patients.

85 Placebo effects in treatment of three anxiety disorders

86 importantly, opens the doors to account for placebo effects in unblinded trials.

87 Vasopressin agonists boosted placebo effects in women but had no effect in men.

88 e therapies are accompanied by a substantial placebo effect, indicating that inhibitory circuits in t

89 k of efficacy could be due to a considerable placebo effect; insensitivity of scales to quantify stif

90 The term placebo effect is taken to mean not only the narrow effe

91 s a consequence, the formation of biological placebo effects is now being linked to the concept of re

92 Currently, the placebo effect literature concentrates more on neurobiol

93 eizure reduction traditionally attributed to placebo effect may reflect the natural course of the dis

94 we found no difference between treatment and placebo effects (MD = -0.29, 95% CI -0.62 to 0.05, P = 0

95 Furthermore, the expected placebo effect observed in studies of functional capacit

96 This essay looks at the placebo effect of alternative medicine as a distinct ent

97 ifficult by the fluctuating symptoms and the placebo effect of invasive interventions.

98 lled trials cannot be overemphasized, as the placebo effect of these therapies is probably marked.

99 significance of its own placebo effect, the placebo effect of unconventional medicine is disregarded

100 ly prospective trials directly comparing the placebo effects of unconventional and mainstream medicin

101 There was no placebo effect on FMV or SUA.

102 Also addressed are the identification of placebo effects on drugs, the relevance of active placeb

103 We examine the brain systems underlying placebo effects on pain, autonomic, and immune responses

104 studies attempting to understand the role of placebo effects on patients receiving a drug.

105 ment might be the result of, for instance, a placebo effect or postoperative physiotherapy.

106 Five components of the placebo effect--patient, practitioner, patient-practitio

107 Nonetheless, the possibility of enhanced placebo effects raises complex conundrums.

108 The dominant theories of human placebo effects rely on a notion that consciously percep

109 of antidepressant medication represents the placebo effect, since many depressed patients improve wh

110 alopram was not significantly different from placebo (effect size, 0.03 HAM-D points; 95% CI, -0.7 to

111 redible interval, 0.09 to 0.49]) and topical placebo (effect size, 0.20 [credible interval, 0.02 to 0

112 ferential model) showed that intra-articular placebo (effect size, 0.29 [95% credible interval, 0.09

113 re of 20-25 (9.26 for olanzapine vs 6.70 for placebo; effect size 0.35, 95% CI 0.11-0.60), by 4.74 po

114 he largest vasopressin-induced modulation of placebo effects, suggesting a moderating interplay betwe

115 al interactions strongly contribute to evoke placebo effects that are pervasive in medicine and depen

116 Placebo effects that were evaluated by using a network m

117 ignores the clinical significance of its own placebo effect, the placebo effect of unconventional med

118 tion, pain-touch and pain-pain interactions, placebo effects, the role of attention and emotion in pa

119 ily negative connotations of the very words "placebo effect, " the term should be replaced by "rememb

120 etic variation were examined controlling for placebo effects using general linear and mixed effects m

121 signed a procedure to intentionally induce a placebo effect via overt recruitment in an effort to eva

122 f agave nectar, placebo, and no treatment, a placebo effect was demonstrated, with no additional bene

123 Hydration was well tolerated, and a placebo effect was observed.

124 The evidence that the placebo effect was responsible for progressive intraocul

125 The placebo effect was very strong in this study, demonstrat

126 at for a half century has been known as the "placebo effect." We argue that, as currently used, the c

127 Placebo effects were minimal and associated with the num

128 Treatment and placebo effects were not different in 22 out of 28 prede

129 Importantly, no significant adverse or placebo effects were seen.

130 omised clinical trials (RCTs) to control for placebo effects, which can be large.

131 ake on the difficult task of controlling for placebo effects will allow patients' subjective ratings

132 Understanding these placebo effects will help to improve clinical trial desi

133 yncope, raise the potential of a significant placebo effect with pharmacologic therapy.

134 ory and clinical studies in the field of the placebo effect, with a particular focus on psychiatric d

135 nization device therapy exerts a substantial placebo effect, with evidence of improved functional cap

136 o test for differences between treatment and placebo effects within similar trial populations.

137 The placebo effect yields beneficial clinical results in 60-